Abstract:6011 Background: The excision repair cross-complementation group 1 (ERCC1) enzyme is a key element of the nucleotide excision repair (NER) pathway which removes cisplatin-induced DNA adducts and has been associated with resistance to platinum-based chemotherapy. We assessed the correlation of ERCC1 immunohistochemical expression with objective tumor response and cancer-specific survival in patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) treated with cisplatin-based induction chemotherapy (CBIC). Methods: The initial cohort comprised 107 patients who had received CBIC (modified Al Saraf protocol) from 1992 to 1996 for locally advanced HNSCC. P53 mutations had been previously studied. Pre-therapeutic biopsy samples from 96 patients with a known tumor response were available. Two independent observers blinded to clinical annotations evaluated ERCC1 expression using the H-score protocol. The median H-score value was a priori selected as the cutpoint in order to dichotomize ERCC1 expression for statistical analysis. Results: In 68 cases [71%, 95% CI: 61% - 79%] tumors expressed ERCC1 intensively and diffusely. Using the logistic regression method, the 28 patients [29 %, 95% CI:21%-39%] with tumors expressing ERCC1 at lower levels had a four time greater odds of benefiting from an objective response to chemotherapy [OR 4.3, 95% CI: 1.4 - 13.4; p = 0.01]. ERCC1 and p53 status, but not their association, were independent predictors of tumor response. In a Cox proportional hazard model adjusted on well-established prognosticators including age, T, N, M, tumor differentiation and localization, ERCC1 low expression was associated with a lower risk of cancer death [RR 2.13, 95% CI: 1.03 - 4.43; p=0.04], while p53 status had no prognostic value. Conclusions: Patients with ERCC1 negative tumors are more likely to derive a substantial benefit from CBIC, translated to a lower risk for cancer-related death compared to patients with ERCC1 positive tumors. Large prospective trials should evaluate ERCC1 and other critical biomarkers involved in DNA damage repair process as molecular predictors of responsiveness to chemotherapy in patients with HNSCC. No significant financial relationships to disclose.

Role of the human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage

[Relationship Between ERCC1 Expression and Cisplatin Intervention in Human Lung Adenocarcinoma Cell Lines].

Enhanced Cisplatin Cytotoxicity by RNA Interfering the Excision Repair Cross-complementing Gene 1 in Lung Cancer Cell A549/DDP

High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.

[Relationship Between Nucleotide Excision Repair Gene ERCC1 and Resistance to Cisplatin in Ovarian Cancer].

Excision Repair Cross-Complementation Group 1 Enzyme As a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for Non Small-Cell Lung Cancer

Enhancing Alkylating Agent Resistance Through ERCC2 Gene Transfection in Human Glioma Cell Line

Role of Nucleotide Excision Repair in Cisplatin Resistance

Excision repair cross complementing-1 gene expression in small cell lung cancer and chemo-sensitivity to cisplatin/etoposide regimen

Relationship Between ERCC1 Expression and Efficacy of Neoadjuvant Chemotherapy in the Patients with Non-Small-cell Lung Cancer

Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.

MicroRNA-191 Modulates Cisplatin-Induced DNA Damage Response by Targeting RCC2.

Ercc1 Immunohistochemical Expression And Cancer-Specific Survival In Patients With Locally Advanced Squamous-Cell Carcinoma Of The Head And Neck Treated By Cisplatin-Based Induction Chemotherapy

The Functional Status of DNA Repair Pathways Determines the Sensitization Effect to Cisplatin in Non-Small Cell Lung Cancer Cells.

CRISPR knockout genome-wide screens identify the HELQ-RAD52 axis in regulating the repair of cisplatin-induced single stranded DNA gaps

Excision repair cross-completion 1 and platinum resistance

ERCC1 abundance is an indicator of DNA repair-apoptosis decision upon DNA damage

Expression of ERCC-1 in NSCLC tissue and its value for appraising chemotherapy

Excision Repair Cross Complementation Group1 Immunohistochemical Expression Predicts Objective Response And Cancer-Specific Survival In Patients Treated By Cisplatin-Based Induction Chemotherapy For Locally Advanced Head And Neck Squamous Cell Carcinoma

Enhanced Cisplatin Cytotoxicity by RNA Interfering the Excision Repair Cross-Complementing 1 Gene in Ovarian Cancer Cell Lines

ERCC1 As a Risk Stratifier in Platinum-Based Chemotherapy for Nonsmall-Cell Lung Cancer.